Onco Wiki / Red flag

Failure to achieve CR after 12 weeks alemtuzumab IV OR rapid relapse — alloSCT urgently;...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "any_of": [
    {
      "finding": "t_pll_no_cr_after_alemtuzumab",
      "value": true
    },
    {
      "finding": "t_pll_rapid_relapse",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Notes

T-PLL median OS without alloSCT ~7-12 months even with alemtuzumab CR. Refractory disease essentially requires transplant or palliative intent.

Used By

Algorithms

• ALGO-T-PLL-2L - ALGO-T-PLL-2L